The stock of Amneal Pharmaceuticals Inc. (NYSE:AMRX) decreased by -$0.12 on Friday to finish at $3.91, down -2.98 percent. The last five days have seen an average of 960,660 shares of common stock traded. 24 times new highs were reached in the current year, with a gain of $1.92. The average number of shares traded over the last 20 days was 1,267,620, while the average volume over the last 50 days totaled 1,209,240.
AMRX stock appreciated 29.04% since last month. On 07/28/23, the company’s shares reached a one-month low of $2.99. The stock touched a high of $4.74 on 08/07/23, after rallying from a low of $1.24 in 52 weeks. The price of AMRX stock has risen by 96.48% or $1.92 this year, reaching a new high 24 times. Still, the stock price is down -17.51% from the 52-week high.
Insider Transactions
AMRX stock investors should be aware that Amneal Pharmaceuticals Inc. (AMRX) stock had its last reported insider trading activity 17 days ago on Aug 11. On Aug 11, Executive Vice President BOYER ANDREW S sold 29,302 shares at $4.13 each. This transaction resulted in the insider making $120,921. On Dec 12, TPG GP A, LLC sold 3,884,600 shares at a price of US$2.34. After the transaction, the insider now owns 12,328,767 shares.
Valuation Metrics
Beta for the stock is 1.25. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 0.53, the price-to-book (PB) ratio of 1.89, and the price-to-cash flow ratio of 10.85.
Financial Health
For the three months ended June 29, Amneal Pharmaceuticals Inc.’s quick ratio was 1.10, while its current ratio was 1.80, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 8.33, and the total debt to equity ratio is 8.81. As far as profitability goes, gross margin for the trailing twelve months is 35.20% percent. Amneal Pharmaceuticals Inc.’s EBITDA margin for the year ended June 29 was 19.92%, whereas its operating margin stood at 8.40% for the same period. Based on annual data, it had gross profit of $784.71 million and revenue of $2.21 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AMRX’s return on assets (ROA) during the last 12 months has been -0.10%. There was a -3.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -0.70%.
Earnings Surprise
According to Amneal Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $599.02 million, while revenues rose by 7.6% to $557.19 million. It was predicted that Amneal Pharmaceuticals Inc.’s quarterly earnings would be $0.19, but it ended up being $0.11, beating the consensus by 72.70%. EBITDA was $139.66 million for the quarter. At the end of Amneal Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 3.55 billion, while its total debt was $2.86 billion. Equity owned by shareholders amounts to $306.31 million.
Technical Picture
Here’s a quick look at Amneal Pharmaceuticals Inc.’s (AMRX) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 53.29%, suggesting the stock is Neutral, with a 60.89% historical volatility rate.
The stochastic %K and %D were 39.55% and 46.02% respectively, while the average true range (ATR) was 0.24. Based on the 14-day stochastic reading of 29.46%, the RSI (14) reading is 56.22%. On the 9-day MACD Oscillator, the stock is at 0.13, and the 14-day reading is at 0.03.
Analyst Ratings
Analysts have assigned Amneal Pharmaceuticals Inc. (AMRX) an Overweight rating. AMRX is a stock that is recommended for selling by 1 brokerage firm, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 3 others recommend it as a buy.
What is AMRX’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.00 and $6.00, with a median target price of $5.00. In analyzing these forecasts, the average price target given by analysts for Amneal Pharmaceuticals Inc. (AMRX) is $5.25.
